The multiple sclerosis specialist at the Corinne Goldsmith Dickinson Center for MS at Mount Sinai spoke about risk mitigation in patients with MS and why it's important to choose medicines in an effective way.
"We're very lucky to have so many effective medicines for treating multiple sclerosis but our decisions now are really made in part on how we can use these medicines as safely as possible."
At the Americans Committee for Treatment and Research for Multiple Sclerosis (ACTRIMS) annual meeting, held in Dallas, Texas, Stephen Krieger, MD, spoke about risk mitigation in multiple sclerosis.
Krieger explained that while the space has several effective medicines available for treatment, a major factor in prescribing comes down to how the medicines can be used as safely as possible. He also elaborated on the fact that while there isn’t a perfect biomarker, the biomarkers that are available for risks helps clinicians maximize the benefit:risk ratio of the medicines for an individual patient.
The multiple sclerosis specialist at the Corinne Goldsmith Dickinson Center for MS at Mount Sinai sat down with NeurologyLive at the meeting for an interview to speak further on the topic.
Related Content:Americas Committee for Treatment and Research in Multiple Sclerosis | Conferences | News | Multiple Sclerosis